Abstract:
The aim of this study was to prepare and characterize Risperidone nanosuspension to
enhance the dissolution rate and oral bioavailaility of this drug. Risperidone is a BCS
class II drug with high permeability and low solubility. Nanosuspensions are
promising candidates that can be used for enhancing the dissolution of poorly water
soluble drugs. In the present work, Nanosuspension was prepared using media
milling method. One mg Risperidone in 10 ml distilled water were prepared in 20 ml
vials using ZrO2 beads (0.4-0.7 mm) as a milling medium and different concentration
of stabilizer. Prepared nanosuspension was evaluated for saturation solubility, mean
particle size, zeta potential and drug release properties. It was observed that optimized
batch F9 containing 25mg of stabilizer and 7 gm of ZrO2 beads having particle size of
217.4 nm with PDI 0.015 and zeta potential of -29.3 mV. The in-vitro drug release of
the Risperidone nanosuspension was enhanced 91.92% in 60 min, relative to that of
plain drug having 34.35% drug release in 60 min and marketed powder for suspension
showed 47.36%. The particle size of batch F9 was 16.84 μm in suspension and 217.4 nm in nanosuspension, i.e. particle size decreased from μm to nm. It leads to
increased particle surface area and solubility of drug.